Previous 10 | Next 10 |
MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced today that the independent Data and Safety Monitoring Board (DSMB) for its ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax ( NVAX ) has dropped to a price that looks cheap if it manages to hit the low end of analyst earnings estimates. However, it’s still trading at a premium to a “worst case scenario” valu...
MALVERN, Pa., April 19, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, wi...
Although it had good news to report, Ocugen (NASDAQ: OCGN) nevertheless saw its stock decline by almost 6% on Monday. That news clearly wasn't good enough for investors, who were likely concerned about the company's lack of specifics. Ocugen announced that it had secured the rig...
Casa Systems (CASA) +41% as Verizon buys 9.9% stake. Natus Medical (NTUS) +28% to be acquired by Archimed Group for $33.50/share in cash or $1.2B. MedAvail Holdings (MDVL) +14%. IMARA (IMRA) +11%. Ocugen (OCGN) +7% on commercialization rights for COVID vaccine Co...
Ocugen (NASDAQ:OCGN) and Bharat Biotec amended their agreement to expand Ocugen’s exclusive territory to include commercialization of COVID vaccine Covaxin in Mexico. Malvern, Pa.-based Ocugen said it gives the the company commercialization rights for Covaxin in all of North...
• Ocugen responsible for commercialization of COVAXIN™ in Mexico • COVAXIN™, already authorized for emergency use in adults by health regulators in Mexico, has been submitted for Emergency Use Authorization for children aged 2-18 years MA...
Although things have improved, we are still in the midst of a pandemic. One important reason we are getting closer to some sort of pre-pandemic normal is that vaccines for the disease are now widely available in many countries. Still, we can never have too many safe and effective vaccines, ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen (NASDAQ: OCGN ) has had a rough week. On Tuesday, the U.S. Food and Health Administration (FDA) announced that it had placed a clinical hold on the Phase 2/3 study of Covaxin, the company’s coronavirus...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lixte Biotechnology (NASDAQ: LIXT ) stock is rocketing higher on Tuesday after the pharmaceutical company revealed pre-clinical results for one of its treatments. Source: CI Photos / Shutterstock.com This data...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...